{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.2","upperLimit":"53.0","value":"30.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Median point estimate and full range will be documented, since only two patients achieved a response.","dispersionType":"Full Range","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"MEDIAN","populationDescription":"Only 2 patients achieved a response.","reportingStatus":"POSTED","timeFrame":"From the time measurement criteria are met for CR or PR (whichever is first) until the first date that recurrence or progression is objectively documented, assessed up to 60 months after the last dose of vorinostat max. treatment duration= 24 months","title":"Response Duration (RD)","type":"SECONDARY","unitOfMeasure":"months"}